These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11553969)

  • 21. Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model.
    Maetzler W; Berg D; Schalamberidze N; Melms A; Schott K; Mueller JC; Liaw L; Gasser T; Nitsch C
    Neurobiol Dis; 2007 Mar; 25(3):473-82. PubMed ID: 17188882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuroinflammatory processes in Parkinson's disease.
    Hunot S; Hirsch EC
    Ann Neurol; 2003; 53 Suppl 3():S49-58; discussion S58-60. PubMed ID: 12666098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
    Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
    Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inflammation and Parkinson's disease].
    Barcia González C; Herrero Ezquerro MT
    Rev Neurol; 2004 Mar 16-31; 38(6):545-53. PubMed ID: 15054720
    [TBL] [Abstract][Full Text] [Related]  

  • 25. How to improve neuroprotection in Parkinson's disease?
    Hirsch EC
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S332-5. PubMed ID: 18267260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular hydrogen is protective against 6-hydroxydopamine-induced nigrostriatal degeneration in a rat model of Parkinson's disease.
    Fu Y; Ito M; Fujita Y; Ito M; Ichihara M; Masuda A; Suzuki Y; Maesawa S; Kajita Y; Hirayama M; Ohsawa I; Ohta S; Ohno K
    Neurosci Lett; 2009 Apr; 453(2):81-5. PubMed ID: 19356598
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
    Kazantsev AG; Kolchinsky AM
    Arch Neurol; 2008 Dec; 65(12):1577-81. PubMed ID: 19064744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites: implications for selective neurodegeneration in Parkinson's disease.
    Hasegawa T; Matsuzaki-Kobayashi M; Takeda A; Sugeno N; Kikuchi A; Furukawa K; Perry G; Smith MA; Itoyama Y
    FEBS Lett; 2006 Apr; 580(8):2147-52. PubMed ID: 16567160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gazing into the future: Parkinson's disease gene therapeutics to modify natural history.
    Maguire-Zeiss KA; Mhyre TR; Federoff HJ
    Exp Neurol; 2008 Jan; 209(1):101-13. PubMed ID: 18035353
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 'Like a thief in the night': the selectivity of degeneration in Parkinson's disease.
    Saper CB
    Brain; 1999 Aug; 122 ( Pt 8)():1401-2. PubMed ID: 10430827
    [No Abstract]   [Full Text] [Related]  

  • 31. Double-strand RNA dependent protein kinase (PKR) is involved in the extrastriatal degeneration in Parkinson's disease and Huntington's disease.
    Bando Y; Onuki R; Katayama T; Manabe T; Kudo T; Taira K; Tohyama M
    Neurochem Int; 2005 Jan; 46(1):11-8. PubMed ID: 15567511
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is alpha-synuclein the culprit of the Parkinsonian neurodegeneration?
    Kirik D; Gai WP; Jensen PH
    Exp Neurol; 2008 Jan; 209(1):3-4. PubMed ID: 18179907
    [No Abstract]   [Full Text] [Related]  

  • 33. Genetic contributions to Parkinson's disease.
    Huang Y; Cheung L; Rowe D; Halliday G
    Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Out FOXing Parkinson disease: where development meets neurodegeneration.
    Wexler EM; Geschwind DH
    PLoS Biol; 2007 Dec; 5(12):e334. PubMed ID: 18092892
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-hydrolytic functions of acetylcholinesterase. The significance of C-terminal peptides.
    Greenfield SA; Zimmermann M; Bond CE
    FEBS J; 2008 Feb; 275(4):604-11. PubMed ID: 18205834
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-melanin antibodies are increased in sera in Parkinson's disease.
    Double KL; Rowe DB; Carew-Jones FM; Hayes M; Chan DK; Blackie J; Corbett A; Joffe R; Fung VS; Morris J; Riederer P; Gerlach M; Halliday GM
    Exp Neurol; 2009 Jun; 217(2):297-301. PubMed ID: 19289120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rat model of Parkinson's disease with bilateral motor abnormalities, reversible with levodopa, and dyskinesias.
    Paillé V; Henry V; Lescaudron L; Brachet P; Damier P
    Mov Disord; 2007 Mar; 22(4):533-9. PubMed ID: 17230470
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neuroinflammatory processes in Parkinson's disease.
    Hirsch EC; Hunot S; Hartmann A
    Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S9-S15. PubMed ID: 15885630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impairment of microtubule-dependent trafficking by overexpression of alpha-synuclein.
    Lee HJ; Khoshaghideh F; Lee S; Lee SJ
    Eur J Neurosci; 2006 Dec; 24(11):3153-62. PubMed ID: 17156376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease?
    Kish SJ
    Adv Neurol; 2003; 91():39-49. PubMed ID: 12442662
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.